CNBC · General

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

· By Elsa Ohlen
Story summary

The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly's rival pill that was approved this week, Novo Nordisk said Thursday.

Read at CNBC

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.